You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples.
The SEK4.9 million ($585,000) grant will support development studies for the firm's Immray PanCan-d blood based test for the early detection of pancreatic cancer.
The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.
The company received a $1.2 million loan to support its American subsidiary, and a $294,000 grant to help pay for a new R&D facility in the Walloon region of Belgium.
The platform will combine electronic health record technologies with clinical decision support tools to enable physicians to personalize cancer screening decisions.
The firm said that the test may be validated as a prognostic test for colorectal cancer and a predictive test for cancer immunotherapies.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.
A total of 66 projects were awarded the funding as part of the Biomedical Catalyst 2016 funding.
The grant will go toward creating a diagnostic technology center to develop methods for detecting protein biomarkers at the point of care.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.